Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record.

PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support

Open access
Tedford, Ryan J., Hemnes, Anna R., Russell, Stuart D., Wittstein, Ilan S., Mahmud, Mobusher, Zaiman, Ari L., Mathai, Stephen C., Thiemann, David R., Hassoun, Paul M., Girgis, Reda E., Orens, Jonathan B., Shah, Ashish S., Yuh, David, Conte, John V., Champion, Hunter C. · 2008 · Circulation: Heart Failure

Abstract

Background— Pulmonary hypertension (PH) secondary to left heart failure portends a poor prognosis and is a relative contraindication to heart transplantation at many centers. We tested the hypothesis that when PH persists after adequate left ventricle unloading via recent left ventricular assist device (LVAD) therapy, phosphodiesterase type 5A inhibition would decrease PH in this population. Methods and Results— We performed an open-label clinical trial using control patients not receiving therapy. Between 1999 and 2007, 138 consecutive patients undergoing cardiac transplantation evaluation with advanced left ventricular dysfunction, an elevated pulmonary capillary wedge pressure, and PH (defined by a pulmonary vascular resistance (PVR) >3 Woods Units), were treated with LVAD therapy. Fifty-eight of these patients reduced their pulmonary capillary wedge pressure to a value <15 mm Hg (11.8�2.0 mm Hg from baseline 23.2�6.2 mm Hg) 1 to 2 weeks after LVAD implantation, but despite this improvement, the PVR of these patients was only minimally affected (5.65�3.00 to 5.39�1.78 Wood Units). Twenty-six consecutive patients from this group with persistently elevated PVR were started on oral phosphodiesterase type 5A inhibition with sildenafil and titrated to an average of dose of 51.9 mg by mouth 3 times per day. The average PVR in the sildenafil-treated group fell from 5.87�1.93 to 2.96�0.92 Wood Units ( P <0.001) and the mean pulmonary artery pressure fell from 36.5�8.6 to 24.3�3.6 mm Hg ( P <0.0001) and was significantly lower when compared with the 32 LVAD recipients not receiving sildenafil at weeks 12 to 15 after the initial post-LVAD hemodynamic measurements (13 to 17 weeks post-LVAD implantation). In addition, hemodynamic measurements of right ventricular function in sildenafil-treated patients was also improved compared with patients not receiving sildenafil. Conclusions— In patients with persistent PH after recent LVAD placement, phosphodiesterase type 5A inhibition in this open-label trial resulted in a significant decrease in PVR when compared with control patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.108.796789

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 185

Metadata

Authors
Tedford, R. J., Hemnes, A. R., Russell, S. D., Wittstein, I. S., Mahmud, M., Zaiman, A. L., Mathai, S. C., Thiemann, D. R., Hassoun, P. M., Girgis, R. E., Orens, J. B., Shah, A. S., Yuh, D., Conte, J. V., & Champion, H. C.
Venue
Circulation: Heart Failure
Published
2008-11
Volume
1
Issue
4
Pages
213-219
ISSN
  • 1941-3289 (ISSN-L)
  • 1941-3297
OpenAlex
W2118674635
Cited by
185
References
0
FWCI
6.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support. https://app.cochat.ai/papers/10.1161/circheartfailure.108.796789
The paper
Tedford, R. J., Hemnes, A. R., Russell, S. D., Wittstein, I. S., Mahmud, M., Zaiman, A. L., Mathai, S. C., Thiemann, D. R., Hassoun, P. M., Girgis, R. E., Orens, J. B., Shah, A. S., Yuh, D., Conte, J. V., & Champion, H. C. (2008). PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.108.796789

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.